Floatz logo

Recombinant Vaccinia Gm-Csf; Rac Vac Gm-Csf

Wilm's Tumor

Jennerex BiotherapeuticsPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Wilm's Tumor cohort.

Asset / SponsorPhaseRating
Inno-206
Children's National Research Institute
Phase 2BB
(+)-VINCRISTINE
Centre Oscar Lambret
Phase 2BB
Itraconazole
Samsung Medical Center
Phase 4BB
Irinotecan
Centre Oscar Lambret
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Recombinant Vaccinia Gm-Csf; Rac Vac Gm-Csf is also rated in:

colorectal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Ewing sarcomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →